title: A review of the current status of siRNA nanomedicines in the treatment of cancer.
abstract: RNA interference currently offers new opportunities for gene therapy by the specific extinction of targeted gene(s) in cancer diseases. However, the main challenge for nucleic acid delivery still remains its efficacy through intravenous administration. Over the last decade, many delivery systems have been developed and optimized to encapsulate siRNA and to specifically promote their delivery into tumor cells and improve their pharmacokinetics for anti-cancer purposes. This review aims to sum up the potential targets in numerous pathways and the properties of recently optimized siRNA synthetic nanomedicines with their preclinical applications and efficacy. Future perspectives in cancer treatment are discussed including promising concomitant treatment with chemotherapies or other siRNA. The outcomes in human clinical trials are also presented.
authors.affiliation: LUNAM Université, F-49933 Angers, France.
authors.forename: Pauline
authors.initials: P
authors.lastname: Resnier
authors.forename: Tristan
authors.initials: T
authors.lastname: Montier
authors.forename: Véronique
authors.initials: V
authors.lastname: Mathieu
authors.forename: Jean-Pierre
authors.initials: JP
authors.lastname: Benoit
authors.forename: Catherine
authors.initials: C
authors.lastname: Passirani
mesh_terms: D000818:Animals; D016503:Drug Delivery Systems / Q000379:methods*; D015316:Genetic Therapy; D006801:Humans; D009369:Neoplasms / Q000235:genetics / Q000378:metabolism / Q000628:therapy*; D034622:RNA Interference; D034741:RNA, Small Interfering / Q000008:administration & dosage* / Q000235:genetics / Q000627:therapeutic use*
chemical_list: D034741:RNA, Small Interfering